DURHAM, N.C. - Precision BioSciences, Inc. (NASDAQ:DTIL) is progressing with multiple dosing cohorts in its Phase 1/2a ELIMINATE-B trial for chronic hepatitis B while expecting regulatory clearance ...

These days, anyone with a computer can easily create their own digital content. With an internet connection, they can publish their work right away. It hasn’t always been this simple, and it’s mainly ...

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program ...

DURHAM, N.C., May 01, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene ...